Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Innovent Biologics (1801 HK): Unfurling The Growth Momentum, Prospective Pipeline To Take It Forward

Innovent Biologics Inc (1801 HK): Dual Engine Growth Strategy Is Yielding Result

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/innovent-biologics-inc" target="_blank" data-smartkarma-citation="entities:27452:1" rel="noopener">Innovent Biologics Inc (1801 HK)</a> maintains momentum as preliminary 1H26 revenue grows over 50% YoY. In 2025, the company had recorded its maiden net profit of RMB 813M.</li>
<li>Despite an overcrowded PD-1 inhibitor market in China, core oncology product, Tyvyt maintained good growth momentum. Tyvyt is under NDA review for its tenth indications.</li>
<li>Ongoing product launches and robust pipeline will support the growth momentum of the company. In the coming years, Innovent aims to achieve RMB 20B product revenue in 2027.</li>
</ul>



Innovent Biologics Inc (1801 HK) maintains momentum as preliminary 1H26 revenue grows over 50% YoY. In 2025, the company had recorded its maiden net profit of RMB 813M.
Despite an overcrowded PD-1 inhibitor market in China, core oncology product, Tyvyt maintained good growth momentum. Tyvyt is under NDA review for its tenth indications.
Ongoing product launches and robust pipeline will support the growth momentum of the company. In the coming years, Innovent aims to achieve RMB 20B product revenue in 2027.


Jiangsu Hengrui Pharmaceuticals (1276 HK)

Innovent Biologics Inc (1801 HK): 2025 Momentum Continues in 1Q26, Pipeline Strength Promising